Status:
COMPLETED
Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy
Lead Sponsor:
wanglin
Conditions:
Idiopathic Membranous Nephropathy
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen Granule to treat idiopathic membranous nephropathy.
Eligibility Criteria
Inclusion
- Women and men who had a clinic and biopsy-proven idiopathic membranous nephropathy;
- 0g≥24 hour urinary protein≥1.0g;
- serum albumin concentration≥26g/L;
- Chronic Kidney Disease (CKD)≤3 stage (eGFR\>30ml/min/1.73m2 MDRD);
- Willing to participate in the trial and signed an informed consent.
Exclusion
- Secondary membranous nephropathy;
- Patients with one of the following circumstances- malignant tumors or malignancy, HIV infection, a history of mental illness, any serious systemic infection, serious gastrointestinal diseases, circulating hepatitis B surface antigens positive or persistent abnormal serum transaminase, abnormal glucose metabolism or diabetes mellitus;
- Pregnant and lactating women;
- Undergoing other clinical trials.
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT01845688
Start Date
November 1 2011
End Date
September 1 2016
Last Update
April 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, China, 200032